Corning and SGD Pharma Inaugurate Glass Tubing Facility in Telangana To Expand Pharmaceutical Packaging Manufacturing

▴ SGD Pharma
Corning Incorporated (NYSE: GLW) and SGD Pharma today announced the inauguration of a new glass tubing facility in Telangana, which will expand pharmaceutical manufacturing in the region.

Hyderabad, India – September 22, 2025 – Corning Incorporated (NYSE: GLW) and SGD  Pharma today announced the inauguration of a new glass tubing facility in Telangana, which will  expand pharmaceutical manufacturing in the region. The new facility will bring together Corning’s state-of-the-art Velocity® Vial technology and SGD Pharma’s vial-converting  expertise, helping address capacity challenges and quality requirements in primary glass  packaging. The new plant will manufacture high quality Type I borosilicate glass tubing,  a critical material used for injectable  drug packaging, direct injection  delivery systems, diagnostics, and  biologics. By combining SGD  Pharma’s vial-converting expertise with  Corning’s proprietary Velocity Vial  glass-coating technology, the  collaboration will enhance vial quality,  improve filling-line productivity, and  accelerate the delivery of injectable treatments. With tubing production and vial converting co-located, the facility will also deliver  efficiencies in sustainability and product quality. 

“The inauguration of this facility marks an important milestone in addressing critical regional  needs, such as expanded production capacity, proximity to customers, and the localization of  supply chains,” said Chris Hudson, Vice President and General Manager, Corning Life  Sciences. “This facility will play a vital role in India in accelerating the delivery of injectable  treatments, supporting local pharmaceutical growth, and ensuring safer, more efficient access to  critical medicines.” 

“This joint venture with Corning marks a major milestone in our global growth strategy. By  establishing a state-of-the-art glass tubing facility in Telangana, we are not only securing a  critical part of our supply chain but also bringing world-class technology to one of the fastest growing pharmaceutical markets,” said Olivier Rousseau, CEO, SGD Pharma. “This investment reinforces our commitment to innovation, sustainability, and supporting local  development, while positioning SGD Pharma as a truly global leader in high-quality glass  packaging.” 

The new facility will also allow Corning to better serve customers in the region, ensuring faster  lead times and strengthening supply chain resilience. This localized manufacturing capacity will  also help broaden the adoption of advanced glass tubing solutions for safer and more efficient  delivery of critical medicines. 

“This project reflects a strong commitment to the region and to our long-term vision,” said  Sudhir Pillai, Managing Director, Corning India. “It creates hundreds of local jobs, boosts the  regional economy, and supports India’s aspirations of self-reliance and sustainable growth. At the  same time, it reinforces Corning’s global leadership in pharmaceutical glass packaging,  underscores its vital role in driving progress across the industry, and aligns with our strategy to  localize manufacturing and expand our global presence.” 

“We are proud to inaugurate this state-of-the-art glass tubing facility in Telangana, a testament to  SGD Pharma’s commitment to advancing pharmaceutical manufacturing in India,” said Deepak  Sood, General Manager, SGD Pharma India. “This facility not only strengthens our local  manufacturing capabilities but also enables us to bring Corning’s Velocity Vial technology to the  region—enhancing product quality, improving operational efficiency, and supporting the  evolving needs of our pharmaceutical partners.” 

SGD Pharma joins a growing network of primary-packaging leaders adopting Corning’s cutting edge coating technology. The new site expands Velocity Vial the manufacturing footprint for  Corning’s Velocity Vials and enables easier adoption of the technology by customers across  markets. 

The joint venture between Corning and SGD Pharma was incorporated in April 2023, followed  by a facility groundbreaking in June 2023. Phase one for Velocity Vials production started in  March 2024, followed by tubing production in late 2025. 

About Corning Incorporated 

Corning (www.corning.com) is one of the world’s leading innovators in materials science, with a  170-year track record of life-changing inventions. Corning applies its unparalleled expertise in  glass science, ceramic science, and optical physics, along with its deep manufacturing and  engineering capabilities to develop category-defining products that transform industries and  enhance people’s lives. Corning succeeds through sustained investment in RD&E, a unique  combination of material and process innovation, and deep, trust-based relationships with  customers who are global leaders in their industries. Corning’s capabilities are versatile and  synergistic, which allows the company to evolve to meet changing market needs, while also helping its customers capture new opportunities in dynamic industries. Today, Corning’s markets  include optical communications, mobile consumer electronics, display, automotive, solar,  semiconductors, and life sciences. 

About SGD Pharma 

SGD Pharma (www.sgd-pharma.com) is a global producer of molded and tubular glass for the  pharmaceutical primary packaging Industry. Building on over a century of expertise, we provide  exceptional quality packaging solutions dedicated to parenteral, oral, and nasal products for  every therapeutic application. Our worldwide clients are supported by more than 90 agents and  distributors and benefit from ongoing innovation at our five best-in-class ISO 15378 certified,  GMP compliant manufacturing plants, giving truly global supply chain infrastructure.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026